Treating children with familial hypercholesterolemia (FH) early can help reduce progression of atherosclerosis without adverse events related to growth and development, said Raul Santos, MD, PhD, director, Lipid Clinic at the Heart Institute, and associate professor, University of São Paulo Medical School, Brazil.
Treating children with familial hypercholesterolemia (FH) early can help reduce progression of atherosclerosis without adverse events related to growth and development, said Raul Santos, MD, PhD, director, Lipid Clinic at the Heart Institute. and associate professor, University of São Paulo Medical School, Brazil.
Transcript
Why has early treatment of familial hypercholesterolemia with therapy been controversial?
You know, there's a lot of discussion why we should start treating kids early, right? Because usually atherosclerosis, it starts developing very early, but manifestation will be, let's say, by the age of 40, 45, 50. So, people say, “Oh, maybe you can wait for these kids to become adults and then we could start treating them.” But, actually, we have evidence that if you start treating early, like let's say, the age of 10 or even earlier, we can reduce the progression of atherosclerosis. We can use imaging techniques to show that the disease progression is much, much lower. And actually, we can even regress that. So this is one argument in favor of treating early.
Second, now we have—at least with the statins—20 years of follow-up showing the drugs are safe and they don't compromise growth, sexual development, cognitive function, and everything. And by the way, I think it's important to say that, actually, evolocumab was very safe regarding growth, sexual development, steroid hormones, lack of soluble vitamins. So, actually, we measured all of that and in the kids it was great. And with the statins, it’s the same thing. So, I think it's time to stop this controversy and start, of course, if we understand that those kids have enough risk, very high [low-density lipoprotein cholesterol], bad family history, start treatment as soon as possible.
What are the benefits and risks of early treatment?
You know, actually, lipid-lowering therapy for kids is very safe. There might be some concern that because kids might need cholesterol for growing up, for brain development, there might be some trouble with that, but this is not true. Actually, we saw in in HAUSER, we didn't see any adverse events related to growth, pubertal development…neurocognitive function. And actually, we also had seen with the statins, the same thing. So, actually, even if we put, let's say, a very powerful therapy on top of drugs that kids are already taking, we didn't see anything that is bad. Actually, we have follow-ups up to 2 years. Of course, we say 2 years is not a lifetime, but as I said, we have more than 20 years follow-up with the statins and we didn’t see any harm.
Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma
November 30th 2023A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
What We’re Reading: ChatGPT in Health Care; Menthol Ban Meeting; Health System Cyberattack Impact
November 30th 2023ChatGPT is changing health care while also raising questions about artificial intelligence's promises and limitations; 24 Biden officials met with the National Organization of Black Law Enforcement Executives to discuss the FDA’s proposal to ban menthol cigarettes; a recent hospital cyberattack shows how the vulnerability of health care systems can put patients at risk.
Read More
7-Day Dosing of Azacytidine Shows Benefit for Females With High-Risk MDS Not Seen in Males
November 30th 2023Investigators from several medical centers in Japan were surprised to find that women with myelodysplastic syndrome (MDS) had a survival advantage from a 7-day dosing schedule, but that benefit compared with a reduced schedule was not seen in men.
Read More